Salvi M - Search Results

1

Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network.

Salvi M, Dazzi D, Pellistri I, Neri F, Wall JR. Salvi M, et al. Ophthalmology. 2002 Sep;109(9):1703-8. doi: 10.1016/s0161-6420(02)01127-2. Ophthalmology. 2002. PMID: 12208720

2

Thyroid ophthalmopathy.

Salvi MG, Neri F. Salvi MG, et al. Curr Ther Endocrinol Metab. 1994;5:77-81. Curr Ther Endocrinol Metab. 1994. PMID: 7704806 No abstract available.

3

Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural network.

Salvi M, Dazzi D, Pellistri I, Neri F. Salvi M, et al. Thyroid. 2002 Mar;12(3):233-6. doi: 10.1089/105072502753600197. Thyroid. 2002. PMID: 11952045

4

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Salvi M, et al. Eur J Endocrinol. 2007 Jan;156(1):33-40. doi: 10.1530/eje.1.02325. Eur J Endocrinol. 2007. PMID: 17218723 Clinical Trial.

5

Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.

Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P. Salvi M, et al. Clin Immunol. 2009 May;131(2):360-5. doi: 10.1016/j.clim.2008.12.005. Epub 2009 Feb 4. Clin Immunol. 2009. PMID: 19195932

6

Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.

Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Salvi M, et al. Arch Ophthalmol. 2012 Jan;130(1):122-4. doi: 10.1001/archopthalmol.2011.1215. Arch Ophthalmol. 2012. PMID: 22232486 No abstract available.

7

Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.

Vannucchi G, Covelli D, Currò N, Dazzi D, Maffini A, Campi I, Bonara P, Guastella C, Pignataro L, Ratiglia R, Beck-Peccoz P, Salvi M. Vannucchi G, et al. Among authors: salvi m. J Clin Endocrinol Metab. 2012 May;97(5):E755-9. doi: 10.1210/jc.2011-2614. Epub 2012 Mar 7. J Clin Endocrinol Metab. 2012. PMID: 22399512

8

A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.

Campi I, Vannucchi GM, Minetti AM, Dazzi D, Avignone S, Covelli D, Currò N, Ratiglia R, Guastella C, Pignataro L, Beck-Peccoz P, Salvi M. Campi I, et al. Among authors: salvi m. Ophthalmology. 2013 May;120(5):1092-8. doi: 10.1016/j.ophtha.2012.10.041. Epub 2013 Feb 8. Ophthalmology. 2013. PMID: 23399378

9

The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.

Vannucchi G, Covelli D, Campi I, Origo D, Currò N, Cirello V, Dazzi D, Beck-Peccoz P, Salvi M. Vannucchi G, et al. Among authors: salvi m. Eur J Endocrinol. 2013 Nov 22;170(1):55-61. doi: 10.1530/EJE-13-0611. Print 2014 Jan. Eur J Endocrinol. 2013. PMID: 24128430

10

Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.

Currò N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, Dazzi D, Guastella C, Pignataro L, Beck-Peccoz P, Ratiglia R, Salvi M. Currò N, et al. Among authors: salvi m. Thyroid. 2014 May;24(5):897-905. doi: 10.1089/thy.2013.0445. Epub 2014 Mar 6. Thyroid. 2014. PMID: 24417307

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

466 results

Search Page

Filters